Magnesium deficiency, a risk factor for diabetes



[ad_1]

Author: Dr. Cătălin Colţ

These include: hypertension, angina pectoris, coronary artery disease, cardiac arrhythmias, myocardial infarction, diabetes mellitus, preeclampsia and eclampsia, osteoporosis, bronchial asthma, chronic fatigue syndrome, etc.

People suffering from diabetes have low magnesium levels, being among those most affected by the consequences of magnesium deficiency. Intracellular magnesium is a co-factor for a number of enzymes that play an important role in glucose metabolism. Hypomagnesemia is common among people with diabetes and is a risk factor for them, being involved in the reduction of insulin secretion and tyrosine kinase activity in insulin receptors. As a result, there is a decrease in glucose metabolism in adipocytes and in muscle cells and an increase in insulin resistance. According to recent studies, magnesium supplementation has beneficial effects on insulin action and glucose metabolism and can prevent type 2 diabetes.

Effective magnesium preparations are those in which magnesium is organically bound (acetate, citrate, methionate, ascorbate, gluconate, propionate or magnesium). Magnesium mineral salts (chloride, sulfate) can not be absorbed, they often have a laxative effect and thus reduce therapeutic efficacy.

Among the organic salts, magnesium tartrate has a great advantage in magnesium deficiency therapy. Because, in addition to magnesium, it also contains orotic acid. Orotic acid was isolated in 1904 by two Italians, Biscaro and Belloni, treating bovine colostrum proteins with lead acetate. In 1940, it was discovered that orotic acid is a by-product of fodder fodder and is a real and valuable source of protein to stimulate growth. The ovine or caprine colostrum contains the highest concentration of orotic acid. Orotic acid has long been considered a substance that the human body would not be able to produce by itself and therefore was called "vitamin B13". It has protective and cellular qualities due to its role in the synthesis of pyrimidine. Like uridine phosphate, orotic acid is incorporated into the synthesis of RNA, DNA and other metabolic precursors, increasing protein synthesis and optimizing energy metabolism.

Orotic acid has beneficial clinical effects on the body, which add to the beneficial effects of magnesium itself. Second, orotic acid introduces intracellular magnesium, increasing the efficacy of the preparation. The cells in our body are those that need magnesium (be it heart cells, muscle cells, nerve cells, etc.), not the extracellular space! Magnesium orotarate over time has proven not only its efficacy and its main role in the prevention and treatment of cardiovascular diseases, but also an enviable safety profile. Considering the high frequency of cardiovascular complications in people with diabetes mellitus may be the best option. Especially since magnerot®, which contains only magnesium and magnesium only, contains no sugar in the excipients and can be safely administered to people with diabetes.

In addition to meeting the recommended daily intake, a correct magnesium deficiency treatment should last for at least six weeks. If clinical phenomena persist after this time, even if the improvement is observed, it is recommended to prolong the treatment for at least 2 weeks. The treatment can then be repeated whenever necessary. Generally, magnesium deficiency is a chronic condition and magnesium therapy should be chronic.

[ad_2]

Source link